Fabienne Caby1. 1. aINSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), Sorbonne Universités, Pierre-and-Marie-Curie University bService des Maladies Infectieuses et Tropicales, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France. *Members of the writing committee equally contributed to this article.
Abstract
OBJECTIVES: A persistently low CD4/CD8 ratio despite virological control reflects a higher risk of morbidity in HIV-infected individuals. The objective of the study was to assess the probability and determinants of ratio restoration (≥1) during long-term combined antiretroviral therapy (cART). DESIGN: Study cohort based on the French Hospital Database on HIV (ANRS CO4). METHODS: Antiretroviral-naive HIV-1-infected individuals were included if they achieved virological control (plasma HIV RNA ≤ 500 copies/ml) within 9 months following cART, started between 2000 and 2010. Cumulative incidence of ratio restoration after virological control and predictive factors of such a favorable outcome were studied taking into account 'virological failure', 'loss to follow-up', and 'death' as competing risks for ratio restoration. RESULTS: Among the 10012 individuals included, the probability of CD4/CD8 ratio restoration was 30% (95% confidence interval, 29-31) at 8 years, ranging from 17% (15 to 19) among individuals with AIDS, to 45% (41 to 50) in people with CD4 at least 500 cells/μl at cART introduction. The main factors associated with ratio restoration were cART started during primary HIV infection whatever the CD4 cell count, or starting at CD4 at least 500 cells/μl while not in primary HIV infection [subdistribution hazard ratio = 1.67 (95% confidence interval, 1.13-2.47) and 2.26 (1.92-2.66) respectively, compared with starting cART at 200-349 CD4 cells/μl], and starting cART in recent years [subdistribution hazard ratio = 2.38 (2.01-2.83) in 2009-2010, compared with 2000-2002]. Higher baseline CD8 cell count was negatively associated with ratio restoration. CONCLUSION: At 8 years, only one-third of individuals achieved CD4/CD8 ratio restoration with sustained virological control. Treatment at the earliest stage, and starting cART in recent years appeared to be key determinants.
OBJECTIVES: A persistently low CD4/CD8 ratio despite virological control reflects a higher risk of morbidity in HIV-infected individuals. The objective of the study was to assess the probability and determinants of ratio restoration (≥1) during long-term combined antiretroviral therapy (cART). DESIGN: Study cohort based on the French Hospital Database on HIV (ANRS CO4). METHODS: Antiretroviral-naive HIV-1-infected individuals were included if they achieved virological control (plasma HIV RNA ≤ 500 copies/ml) within 9 months following cART, started between 2000 and 2010. Cumulative incidence of ratio restoration after virological control and predictive factors of such a favorable outcome were studied taking into account 'virological failure', 'loss to follow-up', and 'death' as competing risks for ratio restoration. RESULTS: Among the 10012 individuals included, the probability of CD4/CD8 ratio restoration was 30% (95% confidence interval, 29-31) at 8 years, ranging from 17% (15 to 19) among individuals with AIDS, to 45% (41 to 50) in people with CD4 at least 500 cells/μl at cART introduction. The main factors associated with ratio restoration were cART started during primary HIV infection whatever the CD4 cell count, or starting at CD4 at least 500 cells/μl while not in primary HIV infection [subdistribution hazard ratio = 1.67 (95% confidence interval, 1.13-2.47) and 2.26 (1.92-2.66) respectively, compared with starting cART at 200-349 CD4 cells/μl], and starting cART in recent years [subdistribution hazard ratio = 2.38 (2.01-2.83) in 2009-2010, compared with 2000-2002]. Higher baseline CD8 cell count was negatively associated with ratio restoration. CONCLUSION: At 8 years, only one-third of individuals achieved CD4/CD8 ratio restoration with sustained virological control. Treatment at the earliest stage, and starting cART in recent years appeared to be key determinants.
Authors: Rachael A Hughes; Margaret T May; Kate Tilling; Ninon Taylor; Linda Wittkop; Peter Reiss; John Gill; Philipp Schommers; Dominique Costagliola; Jodie L Guest; Viviane D Lima; Antonella d'Arminio Monforte; Colette Smith; Matthias Cavassini; Michael Saag; Jessica L Castilho; Jonathan A C Sterne Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Luuk Gras; Margaret May; Lars Peter Ryder; Adam Trickey; Marie Helleberg; Niels Obel; Rodolphe Thiebaut; Jodie Guest; John Gill; Heidi Crane; Viviane Dias Lima; Antonella dʼArminio Monforte; Timothy R Sterling; Jose Miro; Santiago Moreno; Christoph Stephan; Colette Smith; Janet Tate; Leah Shepherd; Mike Saag; Armin Rieger; Daniel Gillor; Matthias Cavassini; Marta Montero; Suzanne M Ingle; Peter Reiss; Dominique Costagliola; Ferdinand W N M Wit; Jonathan Sterne; Frank de Wolf; Ronald Geskus Journal: J Acquir Immune Defic Syndr Date: 2019-03-01 Impact factor: 3.731
Authors: Jesús Troya; Carlos Dueñas; Idoia Irazola; Ignacio de Los Santos; Sara de la Fuente; Desiré Gil; Cristina Hernández; María José Galindo; Julia Gómez; Elisabeth Delgado; Estela Moreno-García; Guillermo Posada; Teresa Aldámiz; Jose Antonio Iribarren; José Manuel Guerra; Miguel Ángel Morán; Carlos Galera; Javier Fuente; Ana Peláez; Miguel Cervero; María Garcinuño; Marta Montero; Francisco Ceballos; Luis Buzón Journal: Medicine (Baltimore) Date: 2022-06-17 Impact factor: 1.817